ABOUT BOOK

Traditional animal models for human African trypanosomiasis rely on detecting Trypanosoma brucei brucei ~parasitemia in the blood. Testing the efficacy of new compounds in these models is cumbersome because it ~may take several months after treatment before surviving parasites become detectable in the blood. To ~expedite compound screening, we have used a Trypanosoma brucei brucei GVR35 strain expressing ~red-shifted firefly luciferase to monitor parasite distribution in infected mice through noninvasive wholebody ~bioluminescence imaging. This protocol describes the infection and in vivo bioluminescence imaging ~of mice to assess compound efficacy against T. brucei during the two characteristic stages of disease, the ~hemolymphatic phase (stage 1) and the encephalitic or central nervous system phase (stage 2).